Exelixis (EXEL) EBITDA Margin Growth (3y) (2013 - 2026)

Exelixis (EXEL) EBITDA Margin Growth (3y) (2013 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin Growth (3y) (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 9,942.00
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 530.00
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn -1,211.00
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn -623.00
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 Exelixis 14.44 Bn 13.66 Bn 590.86 Mn 3,410.00

Historic Data

Download Data
DateValue
Apr 3, 2026 3,410.00
Jan 2, 2026 5,063.00
Oct 3, 2025 1,951.00
Jul 4, 2025 1,763.00
Apr 4, 2025 1,026.00
Sep 27, 2024 950.00
Jun 28, 2024 1,136.00
Mar 29, 2024 863.00
Dec 29, 2023 805.00
Sep 29, 2023 1,470.00
Jun 30, 2023 -1,254.00
Mar 31, 2023 -1,622.00
Dec 30, 2022 -4,351.00
Sep 30, 2022 -2,248.00
Jul 1, 2022 -1,833.00
Apr 1, 2022 -1,586.00
Oct 1, 2021 -3,982.00
Jul 2, 2021 -1,415.00
Apr 2, 2021 -5,613.00
Jan 1, 2021 -2,218.00